A report on ocusert (author's transl)

The fourth communication on the Ocular Therapeutic System Ocusert (Alza Corp., Palo Alto/Calif.; Federal Republic of Germany: Chemie Grünenthal, Stolberg) deals with experiences of a 24 months follow-up study as well as with the results of an omission test. From the diurnal curves carried out over 24 months, and the regression curves the conclusion can be drawn that the continuous application of pilocarpine has not led either to clinically recognisable changes in morphological structures or to a noticeable decreasing sensitivity to the drug so far. The omission test performed with placebo units shows the effect of intraocular pressure reduction remains reversible.     

Keratoplasty in complicated cases (author's transl)]

Prognosis of corneal surgery has improved considerably owing to certain modern advances such as improved anesthesia, antibiotics, steroids, immunosuppressive drugs, better instruments, etc. Therefore it is now possible with the help of new techniques and medications to obtain very satisfactory results, even in cases which, in the past, were considered hopeless cases. Some examples from the author's personal experience are presented.